Literature DB >> 30183581

Prognostic Factors Analysis for Colon Cancer with Lymph Node Negative.

Ionuţ Vîlcea, Benoit Romain, Serge Rohr, Traean Burcoş.   

Abstract

PURPOSE: The analysis of high risk relapse prognosis factors and their importance regarding recurrence risk for stage I and II colon cancer, according to TNM classification 8th edition, 2017. MATERIAL AND
METHOD: We performed a retrospective analysis regarding the impact of prognosis factors for patients with high recurrence risk in stages I and II. We studied 99 patients with T2, T3 and T4 tumors who suffered a curative resection and whom may or may not present indication for adjuvant chemotherapy according to histoprognostic factors and molecular biomarkers.
Results: We performed a univariate Cox regression which highlighted that male sex is a risk factor for disease relapse (HR=5.53, p 0.05, IC95% = 1.29 to 23.73). Although with a low statistical significance effect, T4 tumors seems to be associated with a poor prognosis regarding disease relapse (HR = 2.56, p = 0.06, IC95% = 0.94 to 6.99) compared to T2 and T3 tumors. Patients with d'MMR (MSI-H) seem to have a more favorable evolution compared to patients with p'MMR (MSS/MSI-L) - HR (d'MMR vs p'MMR) = 0.19, IC95% = 0.02 to 1.61, p = 0.13. Conclusions: We believe that it would be useful for MSS / MSI to be systematically analyzed, our data suggesting a better response of d`MMR patients to adjuvant chemotherapy. The multivariate Cox regression did not identify independent risk factors of relapse. Celsius.

Entities:  

Keywords:  chemotherapy; colorectalcancer; lymphnode; prognosisfactor

Mesh:

Year:  2018        PMID: 30183581     DOI: 10.21614/chirurgia.113.4.503

Source DB:  PubMed          Journal:  Chirurgia (Bucur)        ISSN: 1221-9118


  1 in total

1.  Preoperative Predictors of Lymph Node Metastasis in Colon Cancer.

Authors:  Yansong Xu; Yi Chen; Chenyan Long; Huage Zhong; Fangfang Liang; Ling-Xu Huang; Chuanyi Wei; Shaolong Lu; Weizhong Tang
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.